Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and
mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally
advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative …

Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-
oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the …

Background Clinical benefit of neoadjuvant immunotherapy in resectable esophageal
squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and …

Vascular endothelial growth factor (VEGF) represents a growth factor with important pro-
angiogenic activity, having a mitogenic and an anti-apoptotic effect on endothelial cells …

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …

All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …

Background Both perioperative chemotherapy and postoperative chemoradiotherapy
improve survival in patients with resectable gastric cancer from Europe and North America …